免責聲明：本網頁內容不能做為醫師及本協會對個人的正式醫療行為及解說。個人的醫療及解說須以醫療院所正式的診斷及醫療為依據。
站內關鍵字搜尋
| 症狀 | 醫療測試方法 | 測試期別 |
| Neurofibromatosis, Plexiform Neurofibromas | Drug: Sutent®/Sunitinib | Phase 2 |
| Neurofibromatosis Type 1, Cutaneous Neurofibromas | Drug: Ranibizumab | Phase 0 |
| Neurofibromatosis Type 1 | Drug: Methotrexate | Phase 2 |
| Precancerous Condition | Drug: Vinblastine | |
| Neurofibromatosis, Neurofibromas | Drug: Gleevec | Phase 1 |
| Phase 2 | ||
| Neurofibromatosis 2 | Drug: RAD001 | Phase 2 |
| Neurofibromatosis, Neurofibromas | Drug: Tasigna | Phase 0 |
| Neurofibroma, Plexiform | Drug: PLX3397 | Phase 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | |
| Leukemia, Prolymphocytic, Acute | ||
| Sarcoma | ||
| Neurofibromatosis 1 | Drug: Everolimus | Phase 2 |
| Neurofibromatosis Type 1 | Biological: filgrastim | Phase 2 |
| Sarcoma | Drug: doxorubicin hydrochloride | |
| Drug: etoposide | ||
| Drug: ifosfamide | ||
| Procedure: conventional surgery | ||
| Radiation: radiation therapy |
在本網頁提供的資料僅供參考，並非對醫療上的建議，也不構成上市臨床活動的認可。以上是美國和歐洲的資訊來源所整理的醫療試驗。
李銘仁整理 2015-12-07